Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis
暂无分享,去创建一个
S. Kamphuis | P. H. Hissink Muller | E. Hoppenreijs | J. Berg | L. Pachman | F. Wijk | J. Wienke | W. Armbrust | K. Gelderman | T. Arkachaisri | Gabrielle A. Morgan | J. G. Yeo | Maria C Amoruso | A. Royen-Kerkhof | V. Hans | Gabrielle Morgan
[1] C. Minetti,et al. Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features , 2019, Arthritis & rheumatology.
[2] S. Kamphuis,et al. Galectin‐9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation , 2019, Arthritis & rheumatology.
[3] T. Jacques,et al. Expression of myxovirus‐resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis , 2018, Neuropathology and applied neurobiology.
[4] L. Wedderburn,et al. Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools , 2018, Front. Immunol..
[5] Takuya Inoue,et al. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. , 2018, Rheumatology.
[6] K. Rostásy,et al. Pattern of myogenesis and vascular repair in early and advanced lesions of juvenile dermatomyositis , 2018, Neuromuscular Disorders.
[7] C. Papadopoulou,et al. The Vasculopathy of Juvenile Dermatomyositis , 2018, Front. Pediatr..
[8] L. L. van den Hoogen,et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome , 2018, Annals of the rheumatic diseases.
[9] W. Stenzel,et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis , 2018, Brain : a journal of neurology.
[10] C. Bodemer,et al. Myogenic Progenitor Cells Exhibit Type I Interferon–Driven Proangiogenic Properties and Molecular Signature During Juvenile Dermatomyositis , 2018, Arthritis & rheumatology.
[11] G. Shaddick,et al. Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort , 2017, Journal of autoimmunity.
[12] F. Rieux-Laucat,et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.
[13] N. Wulffraat,et al. Consensus-based recommendations for the management of juvenile dermatomyositis , 2016, Annals of the rheumatic diseases.
[14] C. Bodemer,et al. Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease , 2016, Journal of Clinical Immunology.
[15] M. De Iorio,et al. Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis , 2016, Arthritis care & research.
[16] C. Bodemer,et al. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. , 2015, Rheumatology.
[17] J. Gottenberg,et al. Incidence and prevalence of inflammatory myopathies: a systematic review. , 2015, Rheumatology.
[18] T. Bowden,et al. Timing of Galectin-1 Exposure Differentially Modulates Nipah Virus Entry and Syncytium Formation in Endothelial Cells , 2014, Journal of Virology.
[19] B. Prakken,et al. Correlation of CXCL10, Tumor Necrosis Factor Receptor Type II, and Galectin 9 With Disease Activity in Juvenile Dermatomyositis , 2014, Arthritis & rheumatology.
[20] E. Ferrannini,et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. , 2014, Autoimmunity reviews.
[21] M. Rebelatto,et al. Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis , 2013, Rheumatology.
[22] S. Greenberg,et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients , 2013, Annals of the rheumatic diseases.
[23] E. Tønnesen,et al. Soluble Adhesion Molecules Correlate with Surface Expression in an In Vitro Model of Endothelial Activation , 2013, Basic & clinical pharmacology & toxicology.
[24] Chiang-Ching Huang,et al. Lack of Achievement of a Full Score on the Childhood Myositis Assessment Scale by Healthy Four‐Year‐Olds and Those Recovering From Juvenile Dermatomyositis , 2013, Arthritis care & research.
[25] J. Malley,et al. The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies , 2013, Medicine.
[26] S. Amin,et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. , 2012, Arthritis and rheumatism.
[27] S. Sredni,et al. Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. , 2012, Arthritis and rheumatism.
[28] R. Schneider,et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. , 2011, Rheumatology.
[29] S. Stowell,et al. Degeneration of dystrophic or injured skeletal muscles induces high expression of Galectin-1. , 2008, Glycobiology.
[30] I. Lundberg,et al. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. , 2008, Arthritis and rheumatism.
[31] M. Perretti,et al. Inhibitory control of endothelial galectin‐1 on in vitro and in vivo lymphocyte trafficking , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[32] P. Lachenbruch,et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. , 2008, Arthritis and rheumatism.
[33] A. Paller,et al. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. , 2008, Arthritis and rheumatism.
[34] L. Pachman,et al. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. , 2006, Clinical immunology.
[35] D. Watt,et al. Galectin‐1 Induces Skeletal Muscle Differentiation in Human Fetal Mesenchymal Stem Cells and Increases Muscle Regeneration , 2006, Stem cells.
[36] L. Baum,et al. Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration , 2006, Laboratory Investigation.
[37] T. Libermann,et al. Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.
[38] K. Bove,et al. What more can we learn from muscle histopathology in children with dermatomyositis/polymyositis? , 2006, Clinical and experimental rheumatology.
[39] E. Hoffman,et al. Journal of Autoimmune Diseases BioMed Central , 2006 .
[40] K. Stringer,et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. , 2005, Arthritis and rheumatism.
[41] W. Kuis,et al. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. , 2005, Journal of immunological methods.
[42] Y. Konttinen,et al. Disease-associated increased HIF-1, αvβ3 integrin, and Flt-1 do not suffice to compensate the damage-inducing loss of blood vessels in inflammatory myopathies , 2004, Rheumatology International.
[43] R. Bode,et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. , 2003, Arthritis and rheumatism.
[44] L. Pachman,et al. Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. , 2002, Clinical immunology.
[45] S. Marie,et al. Immunohistological analysis of CD59 and membrane attack complex of complement in muscle in juvenile dermatomyositis. , 2002, The Journal of rheumatology.
[46] O. Volpert,et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.
[47] P. Lachenbruch,et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments , 1997 .
[48] J. Mendell,et al. Microvascular deposition of complement membrane attack complex in dermatomyositis. , 1986, The New England journal of medicine.
[49] A. Bohan,et al. Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.
[50] A. Bohan,et al. Polymyositis and dermatomyositis (second of two parts). , 1975 .